Skip to content

KLRS KLRS Change in Lease Liabilities

Change in Lease Liabilities at other companies

Ocular Therapeutix logo
Ocular TherapeutixOCUL
$1.77M+791%
Kodiak Sciences Inc logo
Kodiak Sciences IncKOD
-$3.19M-17.8%
4D Molecular Therapeutics logo
4D Molecular TherapeuticsFDMT
-$878K-16.4%
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
-$145K-114%
PVL
Palvella TherapeuticsPVLA
-$49K

Other financials

Income statement

See full
Operating income-$11.8M-14.3%
Net income-$10.9M-6.5%
EPS (diluted)-$0.46+81.7%

Balance sheet

See full
Cash & equivalents$34.4M-65.9%
Total debt$1.4M
Total equity$68.6M+7.3%
Total assets$109.8M+6.5%

Cash flow

See full
Operating cash flow-$11.6M-55.6%
CapEx$17.0K
Free cash flow-$7.1M

Valuation

See full
Market cap$96.83M+136%
Enterprise value$63.82M

Returns & leverage

See full
Return on equity-66.6%
Debt / equity
Current ratio12.2×-2.1×

Where this comes from

Reported directly by KLRS in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.

The official record: KLRS’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about KLRS's change in lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is KLRS's change in lease liabilities?
KLRS (KLRS) reported change in lease liabilities of -$37K in Q1 2026.
What does change in lease liabilities mean?
Cash payments for operating leases reducing the lease liability, partially offset by new lease commencements.